Cerus (CERS) Set to Announce Earnings on Thursday

Cerus (NASDAQ:CERS) will be posting its quarterly earnings results after the market closes on Thursday, May 2nd. Analysts expect Cerus to post earnings of ($0.04) per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

Cerus (NASDAQ:CERS) last issued its quarterly earnings results on Tuesday, March 5th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.01). The firm had revenue of $46.77 million for the quarter, compared to analyst estimates of $46.80 million. Cerus had a negative return on equity of 67.17% and a negative net margin of 23.98%. On average, analysts expect Cerus to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Cerus Trading Down 3.1 %

Shares of CERS stock opened at $1.70 on Tuesday. The company has a quick ratio of 1.55, a current ratio of 2.14 and a debt-to-equity ratio of 1.12. Cerus has a 52 week low of $1.21 and a 52 week high of $3.08. The firm has a 50 day moving average of $1.94 and a 200-day moving average of $1.86.

Insider Activity at Cerus

In related news, CFO Kevin Dennis Green sold 21,497 shares of the stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $1.97, for a total value of $42,349.09. Following the completion of the sale, the chief financial officer now directly owns 618,750 shares of the company’s stock, valued at approximately $1,218,937.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, SVP Carol Moore sold 20,619 shares of the business’s stock in a transaction that occurred on Wednesday, March 13th. The stock was sold at an average price of $2.02, for a total value of $41,650.38. Following the transaction, the senior vice president now owns 490,623 shares in the company, valued at approximately $991,058.46. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Kevin Dennis Green sold 21,497 shares of the stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $1.97, for a total value of $42,349.09. Following the sale, the chief financial officer now directly owns 618,750 shares of the company’s stock, valued at $1,218,937.50. The disclosure for this sale can be found here. Insiders have sold a total of 177,516 shares of company stock valued at $372,912 over the last 90 days. Insiders own 7.05% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on CERS shares. Craig Hallum began coverage on shares of Cerus in a report on Friday, April 12th. They issued a “buy” rating and a $5.00 price target for the company. Stephens restated an “equal weight” rating and set a $2.50 price objective on shares of Cerus in a report on Thursday, March 7th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $3.00 target price on shares of Cerus in a research report on Wednesday, March 6th.

Cerus Company Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.